Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd has announced a change in the director’s interest, specifically regarding Paul Anderson, who has been issued 52,078 Short-Term Performance Rights following shareholder approval. This adjustment in director’s interest reflects the company’s ongoing commitment to aligning management incentives with shareholder interests, potentially impacting the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd operates in the biotechnology industry, focusing on regenerative medicine. The company develops and commercializes products that repair and regenerate soft tissue injuries, with a market focus on orthopedic and dental applications.
Average Trading Volume: 833,497
Technical Sentiment Signal: Buy
Current Market Cap: A$286M
For an in-depth examination of OCC stock, go to TipRanks’ Overview page.